deltatrials
Terminated PHASE2 INTERVENTIONAL 4-arm NCT02787304

Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)

A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)

Sponsor: Mirum Pharmaceuticals, Inc.

Conditions Non-Alcoholic Steatohepatitis
Interventions Placebo SHP626
Updated 14 times since 2017 Last updated: Nov 6, 2019 Started: Oct 24, 2016 Primary completion: Jul 27, 2018 Completion: Jul 27, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Mirum Pharmaceuticals, Inc.

More terminations from Mirum Pharmaceuticals, Inc.

Other Non-Alcoholic Steatohepatitis trials with similar outcome

Browse all Non-Alcoholic Steatohepatitis trials

A PHASE2 clinical study on Non-Alcoholic Steatohepatitis, this trial is terminated or withdrawn. The trial is conducted by Mirum Pharmaceuticals, Inc. and has accumulated 14 data snapshots since 2016. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jun 2017 · 2 months · monthly snapshot~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Apr 2019 · 7 months · monthly snapshot~Apr 2019 – ~Dec 2019 · 8 months · monthly snapshot~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

▶ Show 9 earlier versions

  1. Dec 2019 — Jan 2021 [monthly]

    Terminated PHASE2

  2. Apr 2019 — Dec 2019 [monthly]

    Terminated PHASE2

  3. Sep 2018 — Apr 2019 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  4. Jul 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  6. Jun 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  7. Apr 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

  8. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mirum Pharmaceuticals, Inc.
Data source: Mirum Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Austin, United States , Baltimore, United States , Birmingham, United Kingdom , Boston, United States , Burlington, United States , Calgary, Canada , Catonsville, United States , Charleston, United States , Charlotte, United States and 50 more locations